Nutex Health (NUTX) Projected to Announce Earnings on Thursday

Nutex Health (NASDAQ:NUTX) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $5.54 per share and revenue of $214.82 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 10:30 AM ET.

Nutex Health (NASDAQ:NUTX) last released its quarterly earnings results on Thursday, August 6th. The company reported $9.38 EPS for the quarter, beating the consensus estimate of $4.95 by $4.43. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. The business had revenue of $210.75 million for the quarter, compared to analysts’ expectations of $215.03 million. On average, analysts expect Nutex Health to post $26.65 EPS for the current fiscal year and $26.76 EPS for the next fiscal year.

Nutex Health Trading Up 0.5%

NUTX stock traded up $0.84 during trading on Tuesday, hitting $186.44. The company had a trading volume of 74,868 shares, compared to its average volume of 166,628. The firm has a 50-day moving average price of $203.24 and a 200-day moving average price of $150.77. Nutex Health has a 12 month low of $83.99 and a 12 month high of $226.16. The company has a quick ratio of 4.96, a current ratio of 5.00 and a debt-to-equity ratio of 0.59. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of 7.32 and a beta of 0.55.

Insider Transactions at Nutex Health

In other news, Director Scott Saunders sold 203 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $214.25, for a total value of $43,492.75. Following the completion of the sale, the director directly owned 400 shares of the company’s stock, valued at $85,700. This represents a 33.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 44.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on NUTX shares. Zacks Research downgraded Nutex Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Weiss Ratings upgraded Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, October 6th. Lake Street Capital reiterated a “buy” rating and issued a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. LADENBURG THALM/SH SH assumed coverage on Nutex Health in a report on Monday, October 26th. They set a “buy” rating and a $336.00 price objective for the company. Finally, B. Riley Financial restated a “buy” rating on shares of Nutex Health in a research report on Friday, September 4th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $323.67.

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.